花旗发表研究报告指，三生制药(01530.HK) 去年收入按年升17%至91亿元人民币，纯利按年升35%至21亿元人民币。集团预测今年收入增长达双位数。
该行将三生制药今年收入及盈利预测分别上调12%及34%，明年收入及盈利预测分别上调17%及43%，将其目标价由6.3元上调至13元，评级由“中性”升至“买入”。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.